原发性胆汁性肝硬化发病相关危险因素研究进展*

doi:10.3969/j.issn.1672-5069.2014.01.035

Abstract

Abstract: Primary biliary cirrhosis（PBC） is considered as an idiopathic autoimmune liver disease,mainly found in middle-aged women. Out of many related risk factors,the demographic factors,environmental factors and genetic factors as well as family history,smoking history and urinary tract infections,have always been thought to be important. In recent years,with the progress in basic and clinical research,especially the application of genome-wide association study technology,scholars found some genes,such as human leukocyte antigen genes,interleukin（IL）-12 and the X chromosome monomer,etc,may lead to this disease. In the future,more samples and GWAS data are needed to verify those new findings to elaborate the pathogenesis of the disease in genetic level.

Key words: Primary biliary cirrhosis, Risk factors, Environmental factors, Hereditary susceptibility

Li Yuanjun, Han Zheyi, Han Ying. Risk factors for the pathogenesis and progression of primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 109-111.

References

[1] Lindor K D,Gershwin M E,Poupon R,et al. Primary biliary cirrhosis. Hepatology,2009,50（1）:291-308.
[2] Smyk D,Rigopoulou E I,Baum H,et al. Autoimmunity and environment:am I at risk. Clin Rev Allergy Immunol,2012,42（2）:199-212.
[3] Lazaridis K N,Juran B D,Boe G M,et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology,2007,46（3）:785-792.
[4] Galbraith R M,Smith M,Mackenzie R M, et al. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med,1974,290（2）:63-69.
[5] Boonstra K,Beuers U,Ponsioen C Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review. J Hepatol,2012,56（5）:1181-1188.
[6] Baldursdottir T R,Bergmann O M,Jonasson J G,et al. The epidemiology and natural history of primary biliary cirrhosis:a nationwide population-based study. Eur J Gastroenterol Hepatol,2012,24（7）:824-830.
[7] Corpechot C,Chretien Y,Chazouilleres O,et al. Demographic, lifestyle,medical and familial factors associated with primary biliary cirrhosis. J Hepatol,2010,53（1）:162-169.
[8] Boone R H,Cheung A M,Girlan L M, et al. Osteoporosis in primary biliary cirrhosis:a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci,2006,51（6）:1103-1112.
[9] Smyk D S,Rigopoulou E I,Muratori L,et al. Smoking as a risk factor for autoimmune liver disease:what we can learn from primary biliary cirrhosis. Ann Hepatol,2012,11（1）:7-14.
[10] Howel D,Fischbacher C M,Bhopal R S,et al. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology,2000,31（5）:1055-1060.
[11] Gershwin M E,Selmi C,Worman H J,et al. Risk factors and comorbidities in primary biliary cirrhosis:a controlled interview-based study of 1032 patients. Hepatology,2005,42（5）:1194-1202.
[12] Ohba K,Omagari K,Kinoshita H,et al. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki,Japan. J Clin Epidemiol,2001,54（8）:845-850.
[13] Kumagi T,Abe M,Ikeda Y,et al. Infection as a risk factor in the pathogenesis of primary biliary cirrhosis: pros and cons. Dis Markers,2010,29（6）:313-321.
[14] Miyakawa H,Tanaka A,Selmi C,et al. Serum reactivity against bacterial pyruvate dehydrogenase:increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis. Clin Dev Immunol,2006,13（2-4）:289-294.
[15] Mattner J,Savage P B,Leung P,et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe,2008,3（5）:304-315.
[16] Van de Water J,Ishibashi H,Coppel R L,et al. Molecular mimicry and primary biliary cirrhosis:premises not promises. Hepatology,2001,33（4）:771-775.
[17] Barzilai O,Sherer Y,Ram M,et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases:are they truly notorious A preliminary report. Ann N Y Acad Sci,2007,1108:567-577.
[18] Bogdanos D P,Baum H,Grasso A,et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol,2004,40（1）:31-39.
[19] Vilagut L,Pares A,Vinas O,et al. Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. Eur J Clin Invest,1997,27（8）:667-672.
[20] Bogdanos D P,Pares A,Baum H,et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun,2004,22（4）:353-362.
[21] Taylor-Robinson D,Sharif A W,Dhanjal N S,et al. Chlamydia pneumoniae infection is an unlikely cause of primary biliary cirrhosis. J Hepatol,2005,42（5）:779-780.
[22] Liu H Y,Deng A M,Zhang J,et al. Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis. World J Gastroenterol,2005,11（26）:4108-4110.
[23] Juran B D,Lazaridis K N. Genetics and genomics of primary biliary cirrhosis. Clin Liver Dis,2008,12（2）:349-365.
[24] Jones D E,Watt F E,Metcalf J V,et al. Familial primary biliary cirrhosis reassessed:a geographically-based population study. J Hepatol,1999,30（3）:402-407.
[25] Hirschfield G M,Liu X,Xu C,et al. Primary biliary cirrhosis associated with HLA,IL12A,and IL12RB2 variants. N Engl J Med,2009,360（24）:2544-2555.
[26] Joshita S,Umemura T,Yoshizawa K,et al. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol, 2010,53（3）:537-541.
[27] Juran B D,Lazaridis K N. Update on the genetics and genomics of PBC. J Autoimmun,2010,35（3）:181-187.
[28] Donaldson P T,Baragiotta A,Heneghan M A,et al. HLA class II alleles,genotypes,haplotypes,and amino acids in primary biliary cirrhosis:a large-scale study. Hepatology,2006,44（3）:667-674.
[29] Onishi S,Sakamaki T,Maeda T,et al. DNA typing of HLA class II genes;DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol,1994,21（6）:1053-1060.
[30] Rong G,Zhou Y,Xiong Y,et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis:the serum cytokine profile and peripheral cell population. Clin Exp Immunol,2009,156（2）:217-225.
[31] Lan R Y,Salunga T L,Tsuneyama K,et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun,2009,32（1）:43-51.
[32] Yoshida K,Yang G X,Zhang W,et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology,2009,50（5）:1494-1500.
[33] Schoniger-Hekele M,Muller C,Ackermann J,et al. Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis. Dig Dis Sci,2002,47（9）:1909-1914.
[34] Invernizzi P,Miozzo M,Battezzati P M,et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet,2004,363（9408）:533-535.
[35] Invernizzi P,Miozzo M,Oertelt-Prigione S,et al. X monosomy in female systemic lupus erythematosus. Ann N Y Acad Sci, 2007,1110:84-91.

Risk factors for the pathogenesis and progression of primary biliary cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[3]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[4]	Qiu Jun, Wang Xueqing, Zhang Bo, et al. Percutaneous choledocholithotomy for the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2019, 22(5): 744-747.
[5]	Zhang Wei, Shi Junmei, Wang Qian. Fisk factors for occurrence of hyperbilirubinemia in neonates [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 534-536.
[6]	Li Fang, Zou Guizhou, Ye Jun, et al. Clinical features and risk factors of patients with decompensated cirrhosis and sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 557-560.
[7]	Du Min, Zhou Min, Ji Zongshu. Clinical features and risk factors of liver injuries in patients with sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 369-372.
[8]	Liu Wenbo, Zhang Jianye, Bao Jiwu. Analysis of risk factors for stone recurrence in patients with common bile duct stones after ERCP and EST therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 437-440.
[9]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[10]	Wang Junyan, Chen Jianting, Zhang Ting, et al.. Risk factors of nosocomial infections in patients with hepatitis B liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 101-104.
[11]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[12]	Zheng Zhenchuan, Xu Xihai.. Pathological and clinical features and factors affecting significant liver fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 713-716.
[13]	Yan Chenli, Wang Jingjing, Wang Jun.. Severity of coronary artery lesions and risk factors in patients with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 737-740.
[14]	Huang Jianwen, Yang Youchao, Xu Changqing. et al. Prognosis of patients with primary liver cancer after radical tumor resection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 521-524.
[15]	Li Furong, Niu Fuyong, Li Hua. Relative levels of S100A6 mRNA and its protein expression in tumorous tissues of patients with cholangiocarcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 541-544.